NCT06058234View on ClinicalTrials.gov

Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study

RecruitingOBSERVATIONAL
Enrollment

8,680

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2029

Conditions
Mild Alzheimer's DiseaseMild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Interventions
DRUG

Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease

FDA approved monoclonal antibodies directed against amyloid for the treatment of AD

Trial Locations (1)

21244

RECRUITING

Centers for Medicare and Medicaid Services, Baltimore

All Listed Sponsors
lead

Centers for Medicare and Medicaid Services/ Coverage and Analysis Group

FED